Eli Lilly and Company $LLY Shares Acquired by Denali Advisors LLC

Key Points

• Denali Advisors increased its Eli Lilly stake by 39% in the second quarter, bringing its holdings to 12,917 shares valued at approximately $15.5 million. Institutional investors collectively own 82.53% of the company.
• Eli Lilly reported quarterly earnings of $8.38 per share and revenue of $22.97 billion, beating analyst expectations, while revenue rose 47.7% year over year. The stock traded at $1,160.98, with a market capitalization of roughly $1.09 trillion and a P/E ratio of 38.96.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $1,292.18. The company also declared a quarterly dividend of $1.73, while insiders sold $15.96 million of shares over the past 90 days under pre-arranged trading plans.

Denali Advisors LLC increased its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 39.0% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,917 shares of the company's stock after purchasing an additional 3,625 shares during the quarter. Eli Lilly and Company makes up 1.6% of Denali Advisors LLC's investment portfolio, making the stock its 6th largest holding. Denali Advisors LLC's holdings in Eli Lilly and Company were worth $15,493,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Mosaic Family Wealth Partners LLC boosted its holdings in shares of Eli Lilly and Company by 70.6% during the second quarter. Mosaic Family Wealth Partners LLC now owns 3,455 shares of the company's stock worth $4,144,000 after purchasing an additional 1,430 shares during the period. Generali Investments Management Co LLC increased its stake in Eli Lilly and Company by 17.5% in the 2nd quarter. Generali Investments Management Co LLC now owns 10,220 shares of the company's stock valued at $12,258,000 after buying an additional 1,521 shares during the period. Moran Wealth Management LLC lifted its position in Eli Lilly and Company by 85.6% in the 2nd quarter. Moran Wealth Management LLC now owns 20,903 shares of the company's stock worth $25,072,000 after buying an additional 9,638 shares in the last quarter. Amundi boosted its stake in shares of Eli Lilly and Company by 9.9% during the 1st quarter. Amundi now owns 5,055,025 shares of the company's stock valued at $4,649,464,000 after buying an additional 454,549 shares during the period. Finally, Whitener Capital Management Inc. grew its holdings in shares of Eli Lilly and Company by 79.3% during the 2nd quarter. Whitener Capital Management Inc. now owns 2,960 shares of the company's stock valued at $3,550,000 after acquiring an additional 1,309 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company's stock.

Eli Lilly and Company Price Performance

NYSE LLY opened at $1,160.98 on Friday. Eli Lilly and Company has a fifty-two week low of $712.05 and a fifty-two week high of $1,292.65. The stock's 50-day moving average is $1,192.90 and its two-hundred day moving average is $1,069.12. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00. The firm has a market cap of $1.09 trillion, a P/E ratio of 38.96, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share for the quarter, topping analysts' consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts' expectations of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business's quarterly revenue was up 47.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, analysts anticipate that Eli Lilly and Company will post 36.35 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. This represents a $6.92 annualized dividend and a yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company's payout ratio is 23.22%.

Insiders Place Their Bets

In other news, EVP Anat Hakim sold 5,000 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the completion of the sale, the executive vice president directly owned 11,875 shares in the company, valued at approximately $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of the company's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the sale, the chief accounting officer directly owned 1,526 shares of the company's stock, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 13,500 shares of company stock valued at $15,958,170 over the last 90 days. 0.14% of the stock is currently owned by company insiders.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Merida acquisition broadens Lilly beyond GLP-1 drugs. Lilly agreed to acquire Merida Biosciences for up to $2.875 billion, adding a platform designed to selectively degrade disease-causing autoantibodies while preserving normal immune function. The deal provides an early-stage pipeline in autoimmune and allergy diseases and represents Lilly’s 10th transaction of 2026, reinforcing management’s effort to diversify its growth drivers. What Does Eli Lilly Gain From Its $2.88 Billion Immunology Deal?
• Positive Sentiment: Clinical and business-development momentum remains favorable. Lilly highlighted its Phase 1 inflammation candidate LY5625575, while its Centessa subsidiary reached a late-stage development milestone for an orexin receptor 2 agonist program. The milestone triggers an $8.6 million payment to partner Nxera Pharma and signals continued progress in Lilly’s broader pipeline. Eli Lilly’s New Phase 1 Inflammation Drug LY5625575 Enters the Spotlight
• Positive Sentiment: Mounjaro expansion into Africa creates a long-term opportunity. Lilly’s partnership with Aspen Pharmacare is initially expected to represent only about 1.25% of quarterly sales, but the launch could establish distribution and market access for Mounjaro across additional African markets. The near-term revenue contribution is small, while the strategic expansion potential is larger. Lilly’s African Mounjaro Push Starts at 1.25% of Quarterly Sales
• Neutral Sentiment: Valuation and execution remain key considerations. Recent coverage points to sustained GLP-1 momentum and Lilly’s strong latest quarter, but the stock trades at a premium valuation. The Merida deal and several early-stage programs could create future growth, although they will require successful clinical development and commercialization.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the stock. UBS Group set a $1,376.00 price target on shares of Eli Lilly and Company in a research note on Friday, August 7th. Royal Bank Of Canada boosted their target price on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the company an "outperform" rating in a research note on Wednesday, July 8th. The Goldman Sachs Group reaffirmed a "buy" rating and issued a $1,283.00 target price on shares of Eli Lilly and Company in a research report on Friday, May 22nd. Weiss Ratings raised Eli Lilly and Company from a "buy (b-)" rating to a "buy (b)" rating in a research note on Wednesday, August 26th. Finally, Wolfe Research reissued an "outperform" rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,292.18.

About Eli Lilly and Company

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source